News | July 22, 2010

Collaboration Increases Awareness About Antiplatelet Therapy

July 22, 2010 – Accumetrics Inc., Daiichi Sankyo Inc., and Eli Lilly and Co. recently announced that they have entered into a strategic collaboration in the United States to raise awareness about antiplatelet therapy and the role of platelet function testing.

Several factors, including a patient’s genetic make-up, diabetic status, age, weight and the use of certain other medications metabolized through the cytochrome P450 pathway in the body may influence patient response to antiplatelet medicines. Therefore, it is important that physicians understand their options to determine if their use of a specific antiplatelet medicine is having its intended effect.

Antiplatelet medicines help prevent blood platelets from sticking or clumping together, reducing the likelihood that arteries will be blocked by a clot, leading to a heart attack.

The focus of the collaboration is to educate health care professionals about the availability and reliability of a rapid and easy-to-use platelet function test, and to stress the importance of assessing each patient’s platelet response to antiplatelet medications.

“We believe physicians will want to know the specific effect of a patient’s antiplatelet therapy and whether additional measures may be needed,” said Rogelio Braceras, M.D., senior medical director, thrombosis at Daiichi Sankyo Inc. “In fact, a recent Clinical Alert from the American College of Cardiology Foundation and American Heart Association noted that several ongoing studies are being conducted to evaluate whether directly measuring the antiplatelet effect might be useful to help tailor antiplatelet therapy for patients.”

This collaborative program will work to provide health care professionals with information about the factors that affect response to antiplatelet medication and how platelet function testing works. Platelet function testing can be measured at the point of care and provides quick insight to physicians about the antiplatelet effect of a specific medicine. With this information, physicians can make more informed treatment decisions.

For more information: www.accumetrics.com, www.dsi.com, www.lilly.com or www.daiichisankyo.com

Related Content

Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Statins Associated With Improved Heart Structure and Function
News | Pharmaceuticals| May 26, 2017
Statins are associated with improved heart structure and function, according to research presented at EuroCMR 2017, May...
Feature | Pharmaceuticals| May 16, 2017
May 16, 2017 – Results of a groundbreaking clinical trial demonstrate the effectiveness of a novel, fast-acting nasal
Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals| May 05, 2017
A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found...
EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals| April 03, 2017
There is no evidence that adding a new cholesterol-lowering drug to treatment with a statin causes memory loss or other...
synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals| March 29, 2017
Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good cholesterol, into the...
heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals| March 28, 2017
When used as a preventive measure during heart surgery, the heart failure drug levosimendan did not significantly...
Overlay Init